(Q55474591)

12 July 2018

title

Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors. (English)

1 reference

12 July 2018

author name string

M Schiebe

1

1 reference

12 July 2018

P Ohneseit

2

1 reference

12 July 2018

W Hoffmann

3

1 reference

12 July 2018

R Meyermann

4

1 reference

12 July 2018

H P Rodemann

5

1 reference

12 July 2018

M Bamberg

6

1 reference

12 July 2018

publication date

1 September 2000

1 reference

12 July 2018

Journal of Neuro-Oncology

published in

1 reference

12 July 2018

volume

49

1 reference

12 July 2018

issue

3

1 reference

12 July 2018

page(s)

197-203

1 reference

12 July 2018

https://scigraph.springernature.com/pub.10.1023/a:1006410702284

exact match

0 references

cites work

The new WHO classification of brain tumours

1 reference

12 December 2020

Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes

1 reference

12 December 2020

Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas

1 reference

12 December 2020

Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors. An analysis of DNA content (ploidy), cellular proliferation, and p53 expression.

1 reference

12 December 2020

mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein

1 reference

12 December 2020

p53 stimulates transcription from the human transforming growth factor alpha promoter: a potential growth-stimulatory role for p53.

1 reference

12 December 2020

MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor

1 reference

12 December 2020

Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.

1 reference

12 December 2020

Gene amplification as a prognostic factor in primary brain tumors

1 reference

12 December 2020

Amplification and overexpression of MDM2 in primary (de novo) glioblastomas.

1 reference

12 December 2020

A comparative study of epidermal growth factor receptor (EGFR) and MDM2 gene amplification and protein immunoreactivity in human glioblastomas.

1 reference

12 December 2020

Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas

1 reference

12 December 2020

Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas.

1 reference

12 December 2020

Biology and treatment of malignant glioma

1 reference

12 December 2020

Phenotype vs genotype in the evolution of astrocytic brain tumors

1 reference

12 December 2020

A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies

1 reference

12 December 2020

Dynamics of genetic alterations associated with glioma recurrence

1 reference

12 December 2020

Prognostic factors in astrocytomas: relationship of p53, MDM-2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival.

1 reference

12 December 2020

Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue.

1 reference

12 December 2020

Amplification at 12q13-14 in human malignant gliomas is frequently accompanied by loss of heterozygosity at loci proximal and distal to the amplification site

1 reference

12 December 2020

The challenge of p53 as prognostic and predictive factor in gliomas

1 reference

12 December 2020

Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival.

1 reference

12 December 2020

Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene

1 reference

12 December 2020

Molecular pathways in the formation of gliomas.

1 reference

12 December 2020

Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification.

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1006410702284

1 reference

12 July 2018

Dimensions Publication ID

1052295207

0 references

1 reference

12 July 2018